|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||
| Cash and due from banks | ||||||||||||||||
| Interest-earning bank balances | ||||||||||||||||
| Due from Federal Reserve Bank | ||||||||||||||||
| Total cash and cash equivalents | ||||||||||||||||
| Securities available-for-sale, at fair value (amortized cost $262,575 and $189,924 at September 30, 2026 and December 31, 2025, respectively) | ||||||||||||||||
| Securities held-to-maturity (fair value $142 and $154 at September 30, 2026 and December 31, 2025, respectively) | ||||||||||||||||
| Loans receivable, net of deferred fees and costs | ||||||||||||||||
| Less: allowance for credit losses for loans | ||||||||||||||||
| Loan receivable, net | ||||||||||||||||
| Bank-owned life insurance | ||||||||||||||||
| Premises and equipment, net | ||||||||||||||||
| Accrued interest receivable | ||||||||||||||||
| Restricted investment in bank stock | ||||||||||||||||
| Deferred taxes, net | ||||||||||||||||
| Goodwill | ||||||||||||||||
| Core deposit intangible | ||||||||||||||||
| Other real estate owned | ||||||||||||||||
| Operating lease right-of-use asset | ||||||||||||||||
| Equity method investments | ||||||||||||||||
| Other assets | ||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||||
| LIABILITIES | ||||||||||||||||
| Deposits: | ||||||||||||||||
| Non-interest-bearing | ||||||||||||||||
| Interest-bearing | ||||||||||||||||
| Total deposits | ||||||||||||||||
| Borrowings | ||||||||||||||||
| Accrued interest payable | ||||||||||||||||
| Operating lease liability | ||||||||||||||||
| Other liabilities | ||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||
| STOCKHOLDERS' EQUITY: | ||||||||||||||||
| Preferred stock, no par value; 2,000,000 shares authorized and none outstanding at September 30, 2026 and at December 31, 2025 | ||||||||||||||||
| Common stock, no par value; 15,000,000 shares authorized, 7,100,002 shares issued and 6,814,076 outstanding at September 30, 2026; 7,042,206 shares issued and 6,765,530 outstanding at December 31, 2025 | ||||||||||||||||
| Paid-in capital | ||||||||||||||||
| Treasury stock, at cost; 285,926 shares at September 30, 2026 and 276,676 shares at December 31, 2025 | ||||||||||||||||
| Retained earnings | ||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||
| TOTAL STOCKHOLDERS' EQUITY | ||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||||
Loading...